• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Rigshospitalet - Product Pipeline Review - Q4 2010 Product Image

Rigshospitalet - Product Pipeline Review - Q4 2010

  • Published: December 2010
  • 64 pages
  • GlobalData

Rigshospitalet – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Rigshospitalet – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by Rigshospitalet.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Rigshospitalet with complete description of the product’s developmental READ MORE >



List of Tables
List of Figures
Rigshospitalet Snapshot
Rigshospitalet Overview
Key Information
Key Facts
Rigshospitalet – Research and Development Overview
Key Therapeutic Areas
Rigshospitalet – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Rigshospitalet – Pipeline Products Glance
Rigshospitalet – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Rigshospitalet Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Rigshospitalet – Drug Profiles
6-Mercaptopurine
Product Description
Mechanism of Action
R&D Progress
6MPindividualized
Product Description
Mechanism of Action
R&D Progress
Bosentan + Sildenafil
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Paclitaxel
Product Description
Mechanism of Action
R&D Progress
Clopidogrel + Aspirin
Product Description
Mechanism of Action
R&D Progress
Immunoglobulin
Product Description
Mechanism of Action
R&D Progress
PEG Asparaginase
Product Description
Mechanism of Action
R&D Progress
Avastin + Tarceva
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Irinotecan
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Irinotecan for Brain Tumors (Rigshospitalet, Denmark)
Product Description
Mechanism of Action
R&D Progress
Bezafibrate
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Paclitaxel + Topotecan Hydrochloride
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Vinorelbine_
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Bevacizumab + Irinotecan
Product Description
Mechanism of Action
R&D Progress
cisplatin + gemcitabine + paclitaxel
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Paclitaxel + Gemcitabine
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Paclitaxel + Gemcitabine + Avastin (Bevacizumab)
Product Description
Mechanism of Action
R&D Progress
Cisplatin + taxotere
Product Description
Mechanism of Action
R&D Progress
Etoposide + Oxaliplatin + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Oxaliplatin + Capecitabine
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Oxaliplatin + Capecitabine for Carcinoma of the bile duct (Rigshospitalet)
Product Description
Mechanism of Action
R&D Progress
Interferon-Beta + Multiferon
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stromal Cells
Product Description
Mechanism of Action
R&D Progress
Progesterone
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Erythropoietin
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy
Product Description
Mechanism of Action
R&D Progress
Tarceva + Avastin
Product Description
Mechanism of Action
R&D Progress
Temsirolimus + Bevacizumab
Product Description
Mechanism of Action
R&D Progress
Trichuris Suis Ova
Product Description
Mechanism of Action
R&D Progress
Rigshospitalet – Pipeline Analysis
Rigshospitalet – Pipeline Products by Therapeutic Class
Rigshospitalet Pipeline Products By Target
Rigshospitalet – Pipeline Products by Route of Administration
Rigshospitalet – Pipeline Products by Molecule Type
Rigshospitalet – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS